(DVAX) |
0 (0%)
|
09-28 21:19 |
Open: |
|
Pre. Close: |
|
High:
|
|
Low:
|
|
Volume:
|
0 |
Market Cap:
|
0(M) |
|
|
Technical analysis |
as of: 2023-09-28 4:50:06 PM |
Short-term rate:
|
|
Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
Mid-term rate:
|
|
Target: |
Six months: 17.61 One year: 20.57  |
Support: |
Support1: 13.9 Support2: 13.18 |
Resistance: |
Resistance1: 15.07 Resistance2: 17.61  |
Pivot: |
13.84  |
Moving Average: |
MA(5): 14.24 MA(20): 13.91 
MA(100): 13.2 MA(250): 11.92  |
MACD: |
MACD(12,26): 0 Signal(9): -0.1  |
Stochastic oscillator: |
%K(14,3): 90.4 %D(3): 77.5  |
RSI: |
RSI(14): 62.1  |
52-week: |
High: 15.11 Low: 9.42 |
Average Vol(K): |
3-Month: 1,723 (K) 10-Days: 1,548 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DVAX ] has closed Bollinger Bands are 9.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
14.83 - 14.88 |
14.88 - 14.93 |
Low:
|
14.34 - 14.41 |
14.41 - 14.47 |
Close:
|
14.65 - 14.75 |
14.75 - 14.83 |
|
Company Description |
|
Headline News |
Thu, 28 Sep 2023 Can Dynavax Technologies Corp (DVAX) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver
Thu, 28 Sep 2023 Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why - Nasdaq
Thu, 28 Sep 2023 Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent - Nasdaq
Wed, 27 Sep 2023 Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data - Nasdaq
Tue, 26 Sep 2023 Unveiling Dynavax Technologies (DVAX)'s Value: Is It Really Priced ... - GuruFocus.com
Tue, 26 Sep 2023 Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs - Nasdaq
|
Financial Analysis |
Price to Book Value: |
Neutral |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Neutral |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Neutral |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: |
Sector: |
Industry: |
Shares Out. |
129 (M) |
Shares Float |
122 (M) |
% Held by Insiders
|
0.2 (%) |
% Held by Institutions
|
100.5 (%) |
Shares Short
|
14,030 (K) |
Shares Short P.Month
|
17,020 (K) |
Stock Financials |
EPS
|
0.74 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
4.48 |
Profit Margin (%)
|
24 |
Operating Margin (%)
|
28.9 |
Return on Assets (ttm)
|
8.4 |
Return on Equity (ttm)
|
22.1 |
Qtrly Rev. Growth
|
-76.5 |
Gross Profit (p.s.)
|
3.47 |
Sales Per Share
|
3.56 |
EBITDA (p.s.)
|
1.06 |
Qtrly Earnings Growth
|
-97 |
Operating Cash Flow
|
152 (M) |
Levered Free Cash Flow
|
138 (M) |
Stock Valuations |
PE Ratio
|
19.94 |
PEG Ratio
|
0 |
Price to Book value
|
3.29 |
Price to Sales
|
4.13 |
Price to Cash Flow
|
12.49 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|